Project 2026-D0005

2026-D0005
Diagnostic Protocol for Evaluating the Clinical Performance of VENTANA FOLR1 (FOLR1-2.1) IUO Assay in Determining FOLR1 Status in Tumor Specimens from Platinum-Resistant Ovarian Cancer Patients in AstraZeneca Phase 3 Study D8991C00001
multicentric
Prof. Dr. Viola Heinzelmann-Schwarz
Universitätsspital Basel, Basel
Spital STS AG - Spital Thun - Onkologie- und Hamatologiezentrum, Thun
Spital Thurgau-Kantonsspital Muensterlingen, Spitalcampus 1
Kantonsspital St. Gallen, Rorschacher Str. 95
Universitaets Spital Zuerich (USZ), Frauenklinikstrasse 10
Spital Zollikerberg, Trichtenhauserstrasse 20
clinical trial
C1
Ethikkommission Nordwest- und Zentralschweiz EKNZ
Kantonale Ethikkommission Bern, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Zürich
27.05.2026
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics [RTD])
in vitro diagnostic medical devices CDx